-
Zelluna ASA: New share capital registered
-
Zelluna ASA: Disclosure of large shareholding
-
Zelluna ASA: Disclosure of large shareholding
-
Zelluna ASA: Issuance of shares to Inven2 through set-off of settlement amounts under option and license agreement
-
Zelluna doses first solid tumour patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial
-
Zelluna ASA – Grant of Share Options
-
Zelluna ASA awarded NOK 16 million Research Council of Norway grant
-
Zelluna ASA: Mandatory notification of trade – Return of lent shares following Private Placement
-
Zelluna ASA: New share capital registered
-
Zelluna ASA activates The Royal Marsden as second clinical site for ZIMA-101, expanding clinical execution capabilities
